Clinical Trial Update: Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial evaluating ecallantide in pediatric hereditary angioedema has been withdrawn (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Ecallantide (ecallantide)

Snippet

Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Phase 2, Phase 3 | Status: WITHDRAWN